Emmaus Life Sciences, Inc.

OTCPK:EMMA Stock Report

Market Cap: US$5.6m

Emmaus Life Sciences Past Earnings Performance

Past criteria checks 0/6

Emmaus Life Sciences has been growing earnings at an average annual rate of 47.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 4% per year.

Key information

47.9%

Earnings growth rate

53.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate4.0%
Return on equityn/a
Net Margin-16.7%
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Emmaus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:EMMA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2328-5242
30 Jun 2328-5242
31 Mar 2322-13232
31 Dec 2218-11212
30 Sep 2215-18192
30 Jun 2216-20202
31 Mar 2219-9193
31 Dec 2121-16194
30 Sep 2124-9194
30 Jun 2124-1184
31 Mar 2122-13194
31 Dec 20231192
30 Sep 20240192
30 Jun 2024-24212
31 Mar 2025-32212
31 Dec 1923-55222
30 Sep 1924-87232
30 Jun 1923-54232
31 Mar 1920-84232
31 Dec 1816-73222
30 Sep 188-37222
30 Jun 184-69192
31 Mar 181-33182
31 Dec 171-33163
30 Sep 171-43123
30 Jun 170-32123
31 Mar 170-23102
31 Dec 160-21102
30 Sep 161-19102
30 Jun 161-16102
31 Mar 161-15102
31 Dec 151-13112
30 Sep 150-11111
30 Jun 151-11111
31 Mar 151-18132
31 Dec 141-22132
30 Sep 140-22132
30 Jun 140-23132
31 Mar 140-18112
31 Dec 130-14112
30 Sep 130-15103
30 Jun 130-1493
31 Mar 130-1493

Quality Earnings: EMMA is currently unprofitable.

Growing Profit Margin: EMMA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EMMA is unprofitable, but has reduced losses over the past 5 years at a rate of 47.9% per year.

Accelerating Growth: Unable to compare EMMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EMMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: EMMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.